Latest Breaking News On - Transcription modulator - Page 8 : comparemela.com

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCytarabine annaraTacaribe arenavirusWalter klempJenene thomasPrnewswire moleculin biotech incEuropean unionSecurities exchangeCompany core technologiesDrug administrationNational institutes of healthMoleculin biotech incExchange commissionChief executive officerGeneration anthracyclineRecommended phase

Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast

HOUSTON, May 4, 2023 /PRNewswire/ Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,. | May 4, 2023

United statesJonathan fosterJenene thomasWalter klempJohn paul waymackPrnewswire moleculin biotech incMoleculin biotech incChief executive officerFinancial officerSenior chief medical officerMoleculin biotech conferenceMoleculin biotechTranscription modulatorNc stock exchangePress releaseNd mbrx us60855d2009

Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,.

United statesJenene thomasWalter klempPrnewswire moleculin biotech incExchange commissionDrug administrationMoleculin biotech incSecurities exchangeChief executive officerFast track statusOrphan drug designationMoleculin biotechTranscription modulatorSecurities actSecurities exchange actPrivate securities litigation reform act

Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,.

United statesJenene thomasWalter klempRafal zielinskiExchange commissionOrange county convention centerAmerican association for cancer researchDivision of cancer medicineSecurities exchangeUniversity of texas md anderson cancer centerDepartment of experimental therapeuticsMoleculin biotech incAmerican associationCancer researchAnnual meetingMoleculin biotech

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,.

United statesJenene thomasRafal zielinskiDivision of cancer medicineMoleculin biotech incOrange county convention centerMd anderson cancer centerExchange commissionAmerican association for cancer researchSecurities exchangeDepartment of experimental therapeuticsMoleculin biotechAmerican associationCancer researchAnnual meetingAntitumor agents